Inhibiting monoclonal antibody GDF-15 improves cancer cachexia symptoms

IF 503.1 1区医学 Q1 ONCOLOGY

CA: A Cancer Journal for Clinicians Pub Date : 2025-01-20 DOI:10.3322/caac.21878

Mike Fillon

{"title":"Inhibiting monoclonal antibody GDF-15 improves cancer cachexia symptoms","authors":"Mike Fillon","doi":"10.3322/caac.21878","DOIUrl":null,"url":null,"abstract":"<p>A new phase 2 study found that ponsegromab (Pfizer) helped with issues typically associated with cancer cachexia by suppressing weight loss and improving appetite and physical activity. Researchers found that the monoclonal antibody inhibited the serum level of growth differentiation factor 15 (GDF-15), which is associated with cachexia’s multifaceted syndrome. Currently, there are no medicines approved for treating cancer cachexia.</p>\n<p>“We believe this study is a unique development elevating symptom science because it is a biomarker-driven symptom intervention,” says study author Eric Roeland, MD, an associate professor of medicine in the Division of Hematology/Medical Oncology at the Oregon Health and Science University’s Knight Cancer Institute Clinic in Portland, Oregon.</p>\n<div>\n<figure>\n<div><picture>\n<source media=\"(min-width: 1650px)\" srcset=\"/cms/asset/c2052164-7f9a-4a8c-9432-0086c645d5e7/caac21878-gra-0001-m.jpg\"/><img alt=\"image\" data-lg-src=\"/cms/asset/c2052164-7f9a-4a8c-9432-0086c645d5e7/caac21878-gra-0001-m.jpg\" loading=\"lazy\" src=\"/cms/asset/afbc0190-8fef-4f53-9e11-dc7d8130fa6f/caac21878-gra-0001-m.png\" title=\"image\"/></picture><p></p>\n</div>\n</figure>\n</div>\n<p>The study appears in <i>The New England Journal of Medicine</i> (doi:10.1056/NEJMoa2409515).</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"37 1","pages":""},"PeriodicalIF":503.1000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3322/caac.21878","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

A new phase 2 study found that ponsegromab (Pfizer) helped with issues typically associated with cancer cachexia by suppressing weight loss and improving appetite and physical activity. Researchers found that the monoclonal antibody inhibited the serum level of growth differentiation factor 15 (GDF-15), which is associated with cachexia’s multifaceted syndrome. Currently, there are no medicines approved for treating cancer cachexia.

“We believe this study is a unique development elevating symptom science because it is a biomarker-driven symptom intervention,” says study author Eric Roeland, MD, an associate professor of medicine in the Division of Hematology/Medical Oncology at the Oregon Health and Science University’s Knight Cancer Institute Clinic in Portland, Oregon.

The study appears in The New England Journal of Medicine (doi:10.1056/NEJMoa2409515).

查看原文本刊更多论文

抑制单克隆抗体GDF-15改善癌症恶病质症状

一项新的2期研究发现，ponsegromab（辉瑞）通过抑制体重下降、改善食欲和身体活动，帮助解决与癌症恶病质相关的问题。研究人员发现，单克隆抗体抑制了与恶病质多面综合征相关的血清生长分化因子15 （GDF-15）水平。目前，还没有药物被批准用于治疗癌症恶病质。“我们相信这项研究是一个提升症状科学的独特发展，因为它是一种生物标志物驱动的症状干预，”研究作者Eric Roeland医学博士说，他是俄勒冈州波特兰市俄勒冈健康与科学大学奈特癌症研究所诊所血液学/医学肿瘤学部门的医学副教授。这项研究发表在《新英格兰医学杂志》上（doi:10.1056/NEJMoa2409515）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CA: A Cancer Journal for Clinicians 医学-肿瘤学

CiteScore

873.20

自引率

0.10%

发文量

审稿时长

1 months

期刊介绍： CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.